BR112021005868A2 - Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g - Google Patents

Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g Download PDF

Info

Publication number
BR112021005868A2
BR112021005868A2 BR112021005868-0A BR112021005868A BR112021005868A2 BR 112021005868 A2 BR112021005868 A2 BR 112021005868A2 BR 112021005868 A BR112021005868 A BR 112021005868A BR 112021005868 A2 BR112021005868 A2 BR 112021005868A2
Authority
BR
Brazil
Prior art keywords
sequence
seq
aspects
cdr
molecule
Prior art date
Application number
BR112021005868-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Courtney BEERS
John Corbin
Doug Hodges
Achim Moesta
Vanessa Soros
Paul Fredrick Widboom
Joseph Robert Warfield
Original Assignee
Tizona Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68296637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112021005868(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tizona Therapeutics filed Critical Tizona Therapeutics
Publication of BR112021005868A2 publication Critical patent/BR112021005868A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
BR112021005868-0A 2018-09-27 2019-09-26 Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g BR112021005868A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737666P 2018-09-27 2018-09-27
US62/737,666 2018-09-27
PCT/US2019/053158 WO2020069133A1 (en) 2018-09-27 2019-09-26 Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies

Publications (1)

Publication Number Publication Date
BR112021005868A2 true BR112021005868A2 (pt) 2021-10-19

Family

ID=68296637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005868-0A BR112021005868A2 (pt) 2018-09-27 2019-09-26 Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g

Country Status (27)

Country Link
US (4) US11208487B2 (https=)
EP (1) EP3856780A1 (https=)
JP (2) JP7588068B2 (https=)
KR (1) KR102867868B1 (https=)
CN (2) CN115057932B (https=)
AR (2) AR116526A1 (https=)
AU (1) AU2019346598B2 (https=)
BR (1) BR112021005868A2 (https=)
CA (1) CA3114407A1 (https=)
CL (2) CL2021000761A1 (https=)
CO (1) CO2021004719A2 (https=)
CR (1) CR20210197A (https=)
DO (1) DOP2021000049A (https=)
EA (1) EA202190609A1 (https=)
EC (1) ECSP21026339A (https=)
IL (1) IL281778A (https=)
MX (1) MX2021003555A (https=)
MY (1) MY204959A (https=)
NZ (1) NZ774376A (https=)
PE (1) PE20211767A1 (https=)
PH (1) PH12021550690A1 (https=)
SG (1) SG11202103104RA (https=)
TW (2) TWI828767B (https=)
UA (1) UA129052C2 (https=)
UY (1) UY38391A (https=)
WO (1) WO2020069133A1 (https=)
ZA (2) ZA202102034B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
MX2022015498A (es) * 2020-06-11 2023-01-24 Tizona Therapeutics Captadores de celulas inmunitarias biespecificas con especificidad de union para hla-g y otro antigeno.
KR20230147617A (ko) 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
US12012454B2 (en) * 2021-03-24 2024-06-18 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
EP4501964A4 (en) * 2022-03-25 2026-04-22 Hk Inno N Corp SPECIFIC HLA-G ANTIBODY AND ITS USE
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
KR20250009591A (ko) * 2022-04-08 2025-01-17 티조나 테라퓨틱스 항-hla-g 항체 및 항-egfr 항체, 항-pd1 또는 항-pd-l1 항체, 및/또는 항-cd47을 함유하는 복합 치료법
KR20240002205A (ko) * 2022-06-24 2024-01-04 에이치케이이노엔 주식회사 면역관문 제어 인자를 발현하는 면역세포 및 이의 용도
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体，及应用
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119569891B (zh) * 2023-09-06 2025-09-05 上海恩凯细胞技术有限公司 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用
GB202319122D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody
WO2025165879A1 (en) 2024-01-29 2025-08-07 Tizona Therapeutics, Inc. Methods of using anti-hla-g antibodies
WO2025245256A1 (en) 2024-05-22 2025-11-27 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
WO1996031604A1 (en) 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CA2321222A1 (fr) 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
WO2002022784A2 (en) 2000-09-15 2002-03-21 University Of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
WO2002061071A2 (en) 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
US9175064B2 (en) 2003-11-04 2015-11-03 Shuji Miyagawa HLA-E chimeric molecule
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2445935B1 (en) 2009-06-25 2015-07-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
AU2016243128A1 (en) 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
EP3842448A1 (en) 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
AU2017272875B2 (en) * 2016-06-03 2023-10-19 Invectys Anti HLA-G specific antibodies
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.

Also Published As

Publication number Publication date
EP3856780A1 (en) 2021-08-04
CN113166243A (zh) 2021-07-23
JP2022502052A (ja) 2022-01-11
PH12021550690A1 (en) 2022-02-28
US20210340259A1 (en) 2021-11-04
UA129052C2 (uk) 2025-01-01
CN115057932B (zh) 2026-04-21
PE20211767A1 (es) 2021-09-07
AR116526A1 (es) 2021-05-19
JP2024177227A (ja) 2024-12-19
ZA202201874B (en) 2025-05-28
CN115057932A (zh) 2022-09-16
TW202035456A (zh) 2020-10-01
NZ774376A (en) 2025-11-28
CO2021004719A2 (es) 2021-05-31
AU2019346598A1 (en) 2021-04-29
US20220135689A1 (en) 2022-05-05
US11208487B2 (en) 2021-12-28
CA3114407A1 (en) 2020-04-02
US20200102390A1 (en) 2020-04-02
IL281778A (en) 2021-05-31
AU2019346598B2 (en) 2026-02-26
DOP2021000049A (es) 2021-10-31
JP7588068B2 (ja) 2024-11-21
ECSP21026339A (es) 2021-07-30
MX2021003555A (es) 2021-05-27
KR102867868B1 (ko) 2025-10-13
CL2023002048A1 (es) 2023-12-22
US20250353913A1 (en) 2025-11-20
UY38391A (es) 2020-04-30
AR130233A2 (es) 2024-11-20
KR20210098956A (ko) 2021-08-11
CL2021000761A1 (es) 2021-09-10
US12264199B2 (en) 2025-04-01
CN113166243B (zh) 2023-03-24
TW202438522A (zh) 2024-10-01
SG11202103104RA (en) 2021-04-29
ZA202102034B (en) 2022-09-28
WO2020069133A1 (en) 2020-04-02
MY204959A (en) 2024-09-25
CR20210197A (es) 2021-06-03
EA202190609A1 (ru) 2021-08-17
TWI828767B (zh) 2024-01-11

Similar Documents

Publication Publication Date Title
US12264199B2 (en) Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
US20250026850A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US20210107981A1 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
RU2810326C2 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
WO2025054320A1 (en) Anti-ackr4 antibodies, compositions and uses thereof
EA045983B1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
HK40018067A (en) Anti-tigit antigen-binding proteins and methods of use thereof

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER.

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]